



SEngine Precision Medicine Receives CLIA Certification to Deliver Oncologists with Patient-Specific, Next-Generation Treatment Options

Potentially sparing cancer patients unnecessary treatments and improving quality and length of life

SEATTLE, July 11, 2017 -- [SEngine Precision Medicine™](#), the biotechnology innovator identifying personalized cancer therapies, has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Seattle, WA laboratory. SEngine now becomes the first and only clinical laboratory in the U.S. certified to perform customized, high-throughput drug chemosensitivity screening for all solid tumor types on live, patient-derived cells. The diagnostic assay, called [P.A.R.I.S.™](#), employs patent-pending technology.

The Washington State Department of Health performed an exhaustive survey before issuing CLIA certification, ensuring high quality standards, accuracy and reliability of testing. The certification allows SEngine to deliver oncologists screening results of next generation cancer treatments, prioritized for individual patients.

“CLIA certification establishes SEngine Precision Medicine as a leader in personalized cancer treatments. We can now offer patients and their doctors a test to help determine the best drug match for a particular cancer based on high-throughput screening and genomic profiling,” said Dr. Carla Grandori, MD, PhD, and CEO of SEngine Precision Medicine, “We are very excited about our progress in advancing personalized medicine, and plan to make our assays widely available.”

SEngine’s CLIA Laboratory now simultaneously screens up to 120 individual drugs and selected drug combinations on live tumor cells. The results are integrated with DNA sequencing and advanced bioinformatics to prioritize therapies to provide personalized treatment options which match a patient’s unique genomic profile. SEngine has shown that screening can identify personalized treatment options in a matter of weeks.

SEngine’s robotic functional screening capabilities and its unique and expanding bioinformatic-driven database can also improve the success rate of new therapies developed by pharma and can identify the patient population that will benefit from a specific drug. Pharmaceutical companies, research institutions and hospitals would thus be provided with early information about their respective test drugs and associated biomarkers. This will potentially save time and money in drug development by zeroing in on the optimal test drug in trials.

For more information, media interviews and lab tours, please contact:

Stephanie Tatem Murphy
stmurphy@senginemedicine.com
206.732.2165

Find images of SEngine CLIA labs, robotics and senior leadership by [clicking here](#).

401 Terry Ave N | Seattle | WA 98109

connect@senginemedicine.com

THE SEARCH ENGINE FOR IDENTIFYING PERSONALIZED CANCER TREATMENTS